Japanese collaborative study to assess inter-laboratory variation in factor VII activity assays

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 8, 2007, Pages 1686-1692

  Takamiya, Osamu ^a   Ishikawa, S ^b   Ohnuma, O ^c   Suehisa, H ^d   Iijima, K ^e   Kayamori, Y ^f   Bando, S ^g   Higashi, K ^h  

^a SHINSHU UNIVERSITY   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY HOSPITAL   (Japan)

^e TOTTORI UNIVERSITY   (Japan)

^f KYUSHU UNIVERSITY HOSPITAL   (Japan)

^g EHIME UNIVERSITY HOSPITAL   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

Author keywords

Calibration plasma; Factor VII activity; Interlaboratory variability; Standard activity curve; Thromboplastin

Indexed keywords

BLOOD CLOTTING FACTOR 7; RECOMBINANT THROMBOPLASTIN; THROMBOPLASTIN;

AFFINITY CHROMATOGRAPHY; ANTIBODY AFFINITY; ARTICLE; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BLOOD SAMPLING; CALIBRATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DILUTION; HUMAN; JAPAN; JAPANESE; LABORATORY TEST; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

CALIBRATION; CHEMISTRY, CLINICAL; CHROMATOGRAPHY, AFFINITY; FACTOR VII; FACTOR VII DEFICIENCY; HUMANS; JAPAN; LABORATORIES; LABORATORY TECHNIQUES AND PROCEDURES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THROMBOPLASTIN;

EID: 34447635881     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02612.x     Document Type: Article

References (30)

1. Williams WJ, Ernest B, Allan JE, Marshall AL. Hematology, 3rd edn. New York: McGraw-Hill, 1983.
2. Perry DJ. Factor VII deficiency. Br J Haematol 2002; 118: 689-700.
3. McVey JH, Boswell EJ, Takamiya O, Tamagnini G, Valente V, Fidalgo T, Layton M, Tuddenham EG. Exclusion of the first EGF domain of factor VII by a splice site mutation causes lethal factor VII deficiency. Blood 1998; 92: 920-6.
4. Takamiya O, Okimoto Y. Severe FVII deficiency with recurrent intracranial hemorrhages owing to double heterozygosity for a splice site mutation of an IVS4 and a novel nonsense mutation in exon 8 (Gln211→Term). Br J Haematol 2001; 114: 369-74.
5. Rosen ED, Chan JC, Idusogie E, Clotman F, Vlasuk G, Luther T, Jalbert LR, Albrecht S, Zhong L, Lissens A, Schoonjans L, Moons L, Collen D, Castellino FJ, Carmeliet P. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature 1997; 390: 290-4.
6. McVey JH, Boswell E, Mumford AD, Kemball-Cook G, Tuddenham EG. Factor VII deficiency and the FVII mutation database. Hum Mutat 2001; 17: 3-17.
7. Cooper DN, Millar DS, Wacey A, Banner DW, Tuddenham EG. Inherited factor VII deficiency: Molecular genetics and pathophysiology. Thromb Haemost 1997; 78: 151-60.
8. Millar DS, Kemball-Cook G, McVey JH, Tuddenham EG, Mumford AD, Attock GB, Reverter JC, Lanir N, Parapia LA, Reynaud J, Meili E, von Felton A, Martinowitz U, Prangnell DR, Krawczak M, Cooper DN. Molecular analysis of the genotype-phenotype relationship in factor VII deficiency. Hum Genet 2000; 107: 327-42.
9. Singer JW, Sibley CA. Sensitivity of commercial thromboplastins to factor VII. Am J Clin Pathol 1973; 59: 755-9.
10. Poggio M, Tripodi A, Mariani G, Mannucci PM. Factor VII clotting assay: influence of different thromboplastins and factor VII-deficient plasmas. Thromb Haemost 1991; 65: 160-4.
11. Takamiya O. Monoclonal anti-human factor VII antibody (B101/B1) which recognizes three dimensional structure near Arg at position 79 in1st EGF-like domain. Thromb Haemost 1998; 79: 104-9.
12. Takamiya O. Does the poor correlation between the hemorrhage symptom and the FVIIc of VII factor deficiency have the problem in the quality of the measurement? Journal of the Japanese Society for Laboratory Hematology 2007; 8: 9-15.
13. Takamiya O. Assay of factor VII antigen by enzyme-linked immunosorbent assay (ELISA). The Official Journal of Japanese Society of Laboratory Medicine 1991; 39: 437-41.
14. FVII Mutation Database. London, UK: The Haemostasis Research Group, Medical Research Council Clinical Sciences Centre, 2004. http://europium.csc.mrc.ac.uk; accessed 1 June 2007.
15. Triplett DA, Kocoshis TA, Harms CS. Factor assay (VIII and IX) results in the College of American Pathologists Survey Program (1976-1979). Scand J Haematol Suppl 1980; 37: 116-29.
16. Christensen RL, Triplett DA. Factor assay (VIII and IX) results in the College of American Pathologists Survey Program (1980-1982). Am J Clin Pathol 1983; 4 (Suppl.): 633-42.
17. Arkin CF, Bovill EG, Brandt JT, Rock WA, Triplett DA. Factors affecting the performance of factor VIII coagulant activity assays. Results of proficiency surveys of the College of American Pathologists. Arch Pathol Lab Med 1992; 116: 908-15.
18. Chambless LE, McMahon R, Finch A, Sorlie P, Heiss G, Lyles R, Wu KK. ARIC hemostasis study-III. Quality control. Atherosclerosis Risk in Communities. Thromb Haemost 1993; 70: 588-94.
19. O'Brien DP, Gale KM, Anderson JS, McVey JH, Miller GJ, Meade TW, Tuddenham EG. Purification and characterization of factor VII 304-Gln: A variant molecule with reduced activity isolated from a clinically unaffected male. Blood 1991; 78: 132-14.
20. Takamiya O, Abe S, Yoshioka A, Nakajima K, McVey JH, Tuddenham EG. Factor VII Shinjo: A dysfunctional factor VII variant homozygous for the substitution Gln for Arg at position 79. Haemostasis 1995; 25: 89-97.
21. Massignon D, Moulsma M, Bondon P, Debize G, Abidi H, Buttin T, Bon C, Pillonchery G, Coeur P. Prothrombin time sensitivity and specificity to mild clotting factor deficiencies of the extrinsic pathway: Evaluation of eight commercial thromboplastins. Thromb Haemost 1996; 75: 590-4.
22. Bader R, Mannucci PM, Tripodi A, Hirsh J, Keller F, Solleder EM, Hawkins P, Peng M, Pelzer H, Teijidor LM, Ramirez IF, Kolde HJ. Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids. Thromb Haemost 1994; 71: 292-9.
23. Smith SA, Comp PC, Morrissey JH. Traces of factor VIIa modulate thromboplastin sensitivity to factors V, VII, X, and prothrombin. J Thromb Haemost 2006; 4: 1553-8.
24. Takamiya O, Takeda Y, Kitagawa M. Problems of reference plasma in assay of coagulation factors; Is the assigned values of commercial standard plasma calibrated by WHO standard interchangeable to that of another one? Japanese Journal of Medical Thechnology 1995b; 44: 1516-21.
25. Humphries S, Temple A, Lane A, Green F, Cooper J, Miller G. Low plasma levels of factor VIIc and antigen are more strongly associated with the 10 base pair promoter (-323) insertion than the glutamine 353 variant. Thromb Haemost 1996; 75: 567-72.
26. Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 1991; 11: 540-6.
27. Brandt JT, Triplett DA, Fair DS. Characterization and comparison of immune-depleted and hereditary factor-VII-deficient plasmas as substrate plasmas for factor VII assays. Am J Clin Pathol 1986; 85: 583-9.
28. Miller GJ, Stirling Y, Esnouf MP, Heinrich J, van de Loo J, Kienast J, Wu KK, Morrissey JH, Meade TW, Martin JC, Imeson JD, Cooper JA, Finch A. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: An international study. Thromb Haemost 1994; 71: 38-48.
29. Cinotti S, Paladino E, Morfini M. Accuracy of FVIII: C assay by one-stage method can be improved using hemophilic plasma as diluent. J Thromb Haemost 2006; 4: 828-33.
30. Giansily-Blaizot M, Verdier R, Biron-Adreani C, Schved JF, Bertrand MA, Borg JY, LeCam-Duchez V, Briquel ME, Chambost H, Pouymayou K, Dutrillaux F, Favier R, Martin-Toutain I, Verdy E, Gay V, Goudemand J, Navarro R, Durin A, d'Oiron R, Lambert T, et al. Study group of FVII deficiency: analysis of biological phenotypes from 42 patients with inherited factor VII deficiency: Can biological tests predict the bleeding risk? Haematologica 2004;89: 704-9.